Division of Hematology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
J Thromb Haemost. 2019 Jan;17(1):149-156. doi: 10.1111/jth.14337. Epub 2018 Dec 16.
Essentials Protein Z (PZ) catalyzes PZ-dependent proteinase inhibitor (ZPI) inactivation of factor (F)Xa. Gene-deletion of PZ or ZPI improves coagulation in hemophilia (FVIII knockout) mice. A PZ blocking antibody enhances thrombin generation in human hemophilia plasma. Suppression of the PZ/ZPI pathway may ameliorate the phenotype of severe hemophilia. SUMMARY: Background Hemostasis requires a balance between procoagulant and anticoagulant factors. Hemophiliacs bleed because of a procoagulant deficiency. Targeted reduction in the activity of endogenous anticoagulant pathways is currently being investigated as a means of improving hemostasis in hemophilia. Protein Z (PZ) is a cofactor that serves as a catalyst for PZ-dependent protease inhibitor (ZPI) inactivation of activated factor X at phospholipid surfaces. Objectives To evaluate the effects of PZ or ZPI gene deletion in hemophilic mice, and of blocking PZ in human hemophilic plasma. Methods A tail vein rebleeding assay (TVRB) was developed on the basis of the serial disruption of clots forming over a period of 15 min following tail vein laceration in an anesthetized mouse. Wild-type (WT)/FVIII knockout FVIIIKO, PZ knockout PZKO/FVIIIKO and ZPI knockout ZPIKO/FVIIIKO mice were evaluated in this model, and their plasmas were tested in thrombin generation assays. A mAb against PZ was evaluated in human hemophilic plasma thrombin generation assays. Results The numbers of clot disruptions (mean ± standard error of the mean) in the TVRB were: 4.0 ± 0.9 for WT/FVIIIKO mice; 23.8 ± 1.1 for WT/FVIIIKO mice supplemented with 100% FVIII; 15.2 ± 1.1 for PZKO/FVIIIKO mice; and 14.7 ± 1.2 for ZPIKO/FVIIIKO mice. Thrombin generation in PZKO/FVIIIKO and ZPIKO/FVIIIKO mouse plasmas was similar to that in FVIIIKO plasma supplemented with ~ 15% recombinant FVIII. A mAb against PZ added to human hemophilic plasma enhanced thrombin generation to an extent similar to the addition of ~ 15% FVIII. Conclusions Blockade of the PZ/ZPI system may be sufficient to ameliorate the phenotype of severe hemophilia.
必需蛋白 Z (PZ) 催化 PZ 依赖性蛋白酶抑制剂 (ZPI) 失活因子 (F)Xa。PZ 或 ZPI 的基因缺失可改善血友病 (FVIII 敲除) 小鼠的凝血。PZ 阻断抗体可增强人血友病血浆中的凝血酶生成。抑制 PZ/ZPI 途径可能改善严重血友病的表型。
背景 止血需要促凝和抗凝因子之间的平衡。血友病患者因促凝因子缺乏而出血。目前正在研究靶向降低内源性抗凝途径的活性,作为改善血友病止血的一种手段。蛋白 Z (PZ) 是一种辅助因子,可作为磷脂表面上 PZ 依赖性蛋白酶抑制剂 (ZPI) 失活活化因子 X 的催化剂。
目的 评估 PZ 或 ZPI 基因缺失对血友病小鼠的影响,以及阻断人血友病血浆中的 PZ 的影响。
方法 在麻醉小鼠尾巴静脉切割后 15 分钟内连续破坏形成的血栓的基础上,开发了尾巴静脉再出血测定法 (TVRB)。在该模型中评估了野生型 (WT)/FVIII 敲除 FVIIIKO、PZ 敲除 PZKO/FVIIIKO 和 ZPI 敲除 ZPIKO/FVIIIKO 小鼠,并在凝血酶生成测定中测试了它们的血浆。评估了针对 PZ 的 mAb 在人血友病血浆凝血酶生成测定中的作用。
结果 TVRB 中的血栓破坏次数 (平均值 ± 标准误差) 为:WT/FVIIIKO 小鼠为 4.0 ± 0.9;WT/FVIIIKO 小鼠补充 100% FVIII 为 23.8 ± 1.1;PZKO/FVIIIKO 小鼠为 15.2 ± 1.1;ZPIKO/FVIIIKO 小鼠为 14.7 ± 1.2。PZKO/FVIIIKO 和 ZPIKO/FVIIIKO 小鼠血浆中的凝血酶生成与补充 ~15% 重组 FVIII 的 FVIIIKO 血浆相似。添加到人血友病血浆中的针对 PZ 的 mAb 增强了凝血酶生成,其程度与添加 ~15% FVIII 相似。
结论 阻断 PZ/ZPI 系统可能足以改善严重血友病的表型。